File(s) under permanent embargo
Antidepressant pharmacogenetics
journal contribution
posted on 2013-01-01, 00:00 authored by Ajeet SinghAjeet Singh, C Bousman, C Ng, Michael BerkMichael BerkPurpose of review: This article reviews recent literature published over the period March 2012–August 2013 on antidepressant pharmacogenetics, with a focus on clinical translation and methodological challenges.
Recent findings: Recently, various polymorphisms associated with differential antidepressant efficacy, tolerability, and safety have emerged in association studies, but mixed findings, limited effect sizes, and poor control of confounders have prevented findings translating to practice. Although promising steps have been made, empirically robust clinically translatable pharmacogenetic tests are not yet established. The complex neurobiology of major depressive disorder (MDD) together with the evolving understanding of genetic processes present research challenges for clinical translation.
Summary: Early reports of clinical utility are published. The current evidence base for antidepressant pharmacogenetics is, however, not yet empirically robust enough to inform routine prescribing guidelines. Over the coming years, genetically guided versus unguided trials will help determine if antidepressant pharmacogenetics merits more widespread application.
Recent findings: Recently, various polymorphisms associated with differential antidepressant efficacy, tolerability, and safety have emerged in association studies, but mixed findings, limited effect sizes, and poor control of confounders have prevented findings translating to practice. Although promising steps have been made, empirically robust clinically translatable pharmacogenetic tests are not yet established. The complex neurobiology of major depressive disorder (MDD) together with the evolving understanding of genetic processes present research challenges for clinical translation.
Summary: Early reports of clinical utility are published. The current evidence base for antidepressant pharmacogenetics is, however, not yet empirically robust enough to inform routine prescribing guidelines. Over the coming years, genetically guided versus unguided trials will help determine if antidepressant pharmacogenetics merits more widespread application.
History
Journal
Current Opinion in PsychiatryVolume
27Issue
1Pagination
43 - 51Publisher
Lippincott Williams & WilkinsLocation
Philadelphia, PAPublisher DOI
ISSN
0951-7367Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2013, Lippincott Williams & WilkinsUsage metrics
Categories
No categories selectedKeywords
AntidepressantsPharmacogenomicsPharmacogeneticsMajor depressionBiomarkersScience & TechnologyLife Sciences & BiomedicinePsychiatryMAJOR DEPRESSIVE DISORDERSEROTONIN REUPTAKE INHIBITORSINDUCED SEXUAL DYSFUNCTIONLINKED POLYMORPHIC REGIONGENOME-WIDE ASSOCIATIONSTAR-ASTERISK-DGENETIC-VARIATIONTREATMENT OUTCOMESTREATMENT RESPONSEMENTAL-DISORDERS
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC